IBD Evidence

Ravi

Bioloogiliste ravimite ja uute ravide võrdlus

Esimest korda on võrdlevale küsimusele — milline ravim, mitte kas ravim — olemas metaanalüütilised vastused.

Updated 2 min read 40 citations Evidence strength 5/5

Traatsilmusega endoskoopiline snaar, mida kasutatakse ülemise seedetrakti ja käärsoole polüpektoomiaks
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Mis on muutunud

Kahe aastakümne jooksul põhines tõenduspõhisus ravim-versus-platseebo uuringutel, mis näitasid kliinikutele, et bioloogilised ravimid toimivad, kuid ei andnud vastust, millist neist valida. Võrgustiku metaanalüüs on selle muutnud, kasutades ühiseid võrdlusaluseid, et ravimeetodeid kaudselt pingeritta seada [1][4].

Praktiline tagajärg on see, et esmavaliku ravimit saab nüüd valida põhjendatult, mitte vaikimisi, ning nähtavaks muutuvad erinevused ravimite vahel indutseeriva ja säilitusravi ning tõhususe ja ohutuse osas.

Kaasaegsete ravimite võrdlev tõhusus

Ravimiklassid

Kaasaegsete ravimite klassid IBD ravis
KlassMehhanismMärkused
Anti-TNFBlokeerib kasvaja nekroosifaktor alfatPikim kasutuskogemus; peamine piirang on immunogeensus
Anti-integriinBlokeerib leukotsüütide liikumise sooldeSoole-selektiivne, mistõttu süsteemne ohutusprofiil on soodne
Anti-IL-12/23 ja anti-IL-23Blokeerib interleukiini signaaliülekannetTugev tõhusus- ja ohutusprofiil viimastes võrdlustes
JAK inhibiitoridVäikemolekul, rakusisene signaaliülekanneSuukaudne ja kiiretoimeline; kardiovaskulaarsete ja tromboosiriskide hoiatused
S1P modulaatoridSekvestreerib lümfotsüüte lümfisõlmedesSuukaudne; uuem, vähem pikaajalisi andmeid

Ravi eesmärgipõhiselt, mitte sümptomite järgi

Kõige olulisem muutus IBD ravikäsitluses on see, et sümptomid on halb põletiku näitaja. Inimesed võivad tunda end hästi, kui põletik on aktiivne, ja halvasti remissiooni ajal. Seetõttu keskendutakse praeguste Euroopa juhiste kohaselt objektiivsetele näitajatele — väljaheite kalprotektiinile, endoskoopilisele paranemisele —, mitte sellele, kuidas patsient ennast tunneb.

See on ka vastus toitumisküsimusele, mis tõstatati lehel toitumine: sekkumine, mis parandab sümptomeid, kuid mitte objektiivseid näitajaid, ei ole haigust ravinud.

Kui ühest ravimist ei piisa

Kahekordset bioloogilist ravi või kombineeritud väikemolekulravi on hinnatud ravile allumatu haiguse korral [3]. See jääb spetsialisti otsustada ning tõendusbaas on piiratud — just siin võib üksikraku tasandi töö, mis iseloomustab ravivastuse heterogeensust [2], kõige tõenäolisemalt praktikat muuta, ennustades, millist mehhanismi konkreetsel patsiendil sihtida, selle asemel et see avastada järjestikuste ravikatsete ebaõnnestumise kaudu.

Bautzeni (Saksamaa) jaamaapteegi hoone tänavavaade
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Korduma kippuvad küsimused

Milline bioloogiline ravim on parim?
Võrgustiku metaanalüüsid seavad need nüüd pingeritta [1][4], ning õige valik sõltub haiguse paiknemisest, raskusastmest, soolevälistest ilmingutest ja teie enda riskitaluvusest.
Kas ma saan ravi lõpetada, kui olen remissioonis?
Ravi lõpetamine kannab endas olulist ägenemise riski. See on otsus, mille tuleb teha koos raviarstidega, tuginedes objektiivsetele näitajatele, mitte enesetundele.
Kas bioloogilised ravimid on ohtlikud?
Neil on tõelised riskid, peamiselt infektsioonid. Ka ravimata põletik kannab endas riski ning võrdlus käib kahe riski, mitte riski ja nullriski vahel.
Milleks on kalprotektiin?
Väljaheite näitaja, mis peegeldab soolepõletikku. Selle abil jälgitaksegi praktikas "ravi eesmärgile suunatult" põhimõtte täitmist.
Selle lehe aluseks olevad tõendid Virnastatud tulpdiagramm, mis näitab sellel leheküljel viidatud 26 publikatsiooni jaotust uuringutüübi kaupa. 26meta-analysis (26)
26 publikatsiooni, 2015–2025. See on suures osas vaatluslik andmebaas. See saab tõestada, et nähtused esinevad koos; see ei suuda kindlaks teha, kumb põhjustab teist. Allikas: selle lehe oma viidete loetelu allpool.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  3. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  4. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  5. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  6. S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations Nast A, Altenburg A, Augustin M, et al. · Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026 · Clinical guideline DOIPubMed 41641952Full text
  7. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  8. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  9. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease Aguas Peris M, Del Hoyo Francisco J, Nos Mateu P, et al. · Gastroenterologia y hepatologia · 2025 · Clinical guideline DOIPubMed 39672505
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease Scott FI, Ananthakrishnan AN, Click B, et al. · Gastroenterology · 2025 · Clinical guideline DOIPubMed 41274746Full text
  12. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Moran GW, Gordon M, Sinopolou V, et al. · Gut · 2025 · Clinical guideline DOIPubMed 40550582
  13. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  14. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  15. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  16. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  17. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  18. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  19. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  20. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  21. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  22. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  23. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  24. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  25. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  26. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  27. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  28. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  29. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients Sicilia B, Vicente R, Arias L, et al. · Gastroenterologia y hepatologia · 2021 · Clinical guideline DOIPubMed 33592179
  30. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  31. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting De Simone B, Davies J, Chouillard E, et al. · World journal of emergency surgery : WJES · 2021 · Clinical guideline DOIPubMed 33971899Full text
  32. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  33. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  34. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  35. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  36. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  37. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  38. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  39. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  40. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original